Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HHK001 vs Enantone in Endometriosis
NCT07793162Phase 1Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Aug 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, randomised, open-label trial of HHK001 in endometriosis (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Maximum Plasma Concentration of Leuprorelin, Area Under the Curve From Time Zero to Last Quantifiable Concentration of Leuprorelin and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
HHK001
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT07793162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793162.